<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas C. Turner(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Anita Grigoriadis(London Cancer), Cheryl Gillett(King's College London), Rachael Natrajan(Institute of Cancer Research), Caterina Marchiò(Candiolo Cancer Institute), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Rachel Sharpe(Guy's Hospital), Andrew Tutt(Institute of Cancer Research), Felipe C. Geyer(Institute of Cancer Research), María Ángeles López‐García(Guy's Hospital), Elizabeth Iorns(Breast Cancer Now), Maryou Lambros(Institute of Cancer Research), Alex Pearson(Breast Cancer Now)
Cited by 740
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k